Wockhardt Limited (WOCKPHARMA) AI Stock Analysis

• Market Cap: ₹223.81B
• Dividend Yield: N/A
• Average Volume (3M): 24.00K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.59
• Revenue Growth: 1.19%
• EPS Growth: 93.08%
• Country: US
• Employees: 2,386
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 4.80
• Shares Outstanding: 162,485,570
• 10 Day Avg. Volume: 15,364
• 30 Day Avg. Volume: 24,000
• PEG Ratio: 5.29
• Price to Book (P/B): 5.18
• Price to Sales (P/S): 7.42
• P/FCF Ratio: -85.35
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: ₹1,449.00 ▲(3.09% Upside)

Wockhardt Limited's overall stock score reflects significant financial challenges, with persistent net losses and negative cash flows being the most impactful factors. Technical analysis shows mixed signals, with short-term strength but potential long-term weakness. The negative P/E ratio and lack of dividend yield further weigh down the score.

Positive Factors

Revenue Growth

The consistent revenue growth indicates Wockhardt's ability to expand its market presence and enhance product adoption, which is crucial for long-term sustainability.

Gross Profit Margin Improvement

Improving gross profit margins suggest enhanced operational efficiency and cost management, which can lead to better profitability over time.

Leverage Reduction

Reduced leverage enhances financial stability and flexibility, allowing Wockhardt to better manage its capital structure and invest in growth opportunities.

Negative Factors

Persistent Net Losses

Ongoing net losses undermine financial health and can limit the company's ability to reinvest in growth, posing a significant risk to long-term viability.

Negative Cash Flow

Negative cash flow indicates that operational activities are not generating sufficient cash, which can strain liquidity and hinder investment in future growth.

Volatile Free Cash Flow

Volatility in free cash flow suggests inconsistent operational efficiency, which can affect the company's ability to fund new projects and manage financial obligations.

Wockhardt Limited Business Overview & Revenue Model

Company Description

Wockhardt Limited, a pharmaceutical and biotechnology company, manufactures and markets active pharmaceutical ingredients, formulations, bio-similars, and vaccines in India, the United States, the United Kingdom, Ireland, Mexico, Russia, and internationally. It develops various molecules primarily in the areas of infectious diseases, such as WCK 5222, WCK 4282, WCK 4873, WCK 771 and WCK 2349, and WCK 6777 molecules. The company's biopharmaceutical products include Glaritus, an insulin analog; Wosulin, an r-DNA insulin; Wepox, a recombinant erythropoietin that is used in the treatment of anemia caused by cancer and chronic renal failure; and Biovac-B, a hepatitis B vaccine. It also provides contract manufacturing services for sterile injectables, lyophilization, and other dosage forms; and research services. The company was founded in 1967 and is headquartered in Mumbai, India. Wockhardt Limited is a subsidiary of Themisto Trustee Company Private Limited.

How the Company Makes Money

Wockhardt Limited generates revenue primarily through the sale of its pharmaceutical products, which include branded and generic drugs, biosimilars, and vaccines. The company's revenue model is diversified across multiple segments, including domestic sales in India and exports to various international markets. Key revenue streams include sales from its core therapeutic areas, particularly in the pharmaceutical and biotechnology sectors. Additionally, Wockhardt benefits from strategic partnerships and collaborations with other pharmaceutical companies, which enhance its research capabilities and market reach. The company also engages in contract manufacturing, providing services to other pharmaceutical firms, which contributes to its overall earnings. Factors such as a strong product pipeline, regulatory approvals for new drugs, and expansion into new markets further bolster its revenue-generating potential.

Wockhardt Limited Financial Statement Overview

Summary

Wockhardt Limited faces significant financial challenges, with negative profitability and cash flow metrics. Despite improvements in revenue and gross profit margins, persistent net losses and negative cash flows pose ongoing risks. The balance sheet is stable with improving leverage ratios, but profitability issues need addressing.

Income Statement

Wockhardt Limited's income statement reflects a challenging financial position. Despite a positive revenue growth of 8.01% in the most recent year, the company has consistently recorded net losses over the past few years, reflected in a negative net profit margin. However, the company has managed to improve its gross profit margin to 33.59% in 2025 from 27.68% in 2024, indicating some operational improvements. Both EBIT and EBITDA margins remain weak, though they show improvement from previous years.

Balance Sheet

The balance sheet of Wockhardt Limited presents a mixed picture. The debt-to-equity ratio has improved to 0.46 in 2025 from 0.70 in 2024, reflecting reduced leverage. The company's equity ratio stands at 53.51%, which indicates a stable capital structure. However, the company has faced declining stockholders' equity in previous years, which poses a risk if not managed effectively. Return on equity remains negative due to persistent net losses.

Cash Flow

Wockhardt Limited's cash flow statement highlights significant cash flow challenges. The operating cash flow has turned negative in the latest year, primarily due to net losses. Free cash flow is also negative, reflecting capital expenditure and investment needs not being met by cash generation from operations. The company has shown a volatile free cash flow growth rate, indicating fluctuating operational efficiency.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	30.34B	30.35B	28.30B	26.57B	32.30B	27.08B
Gross Profit	18.74B	18.26B	15.98B	14.85B	18.81B	14.98B
EBITDA	3.83B	3.60B	1.38B	420.00M	2.26B	-1.43B
Net Income	-1.23B	-470.00M	-4.63B	-5.59B	-2.44B	6.86B
Balance Sheet
Total Assets	0.00	81.35B	76.49B	76.83B	82.43B	77.73B
Cash, Cash Equivalents and Short-Term Investments	5.88B	6.13B	5.23B	1.50B	3.79B	2.38B
Total Debt	0.00	20.21B	23.56B	21.84B	21.98B	26.73B
Total Liabilities	-46.57B	34.78B	39.87B	40.21B	40.41B	40.12B
Stockholders Equity	46.57B	43.53B	33.59B	33.54B	38.49B	33.77B
Cash Flow
Free Cash Flow	0.00	-2.64B	30.00M	-560.00M	2.01B	-4.53B
Operating Cash Flow	0.00	-220.00M	2.19B	1.53B	4.13B	-2.87B
Investing Cash Flow	0.00	-7.83B	-1.37B	-1.25B	-2.01B	14.70B
Financing Cash Flow	0.00	4.09B	3.34B	-3.15B	-710.00M	-11.71B

Wockhardt Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1405.55
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:WOCKPHARMA, the sentiment is Negative. The current price of 1405.55 is below the 20-day moving average (MA) of 1415.86, above the 50-day MA of 1378.66, and below the 200-day MA of 1460.51, indicating a bearish trend. The MACD of -3.62 indicates Positive momentum. The RSI at 44.44 is Neutral, neither overbought nor oversold. The STOCH value of 16.27 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:WOCKPHARMA.

Wockhardt Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUROPHARMA	74 Outperform	₹662.29B	19.03	―	0.33%	7.33%	-3.79%
IPCALAB	74 Outperform	₹376.77B	45.06	―	0.28%	9.66%	25.79%
ALKEM	72 Outperform	₹683.80B	28.65	―	0.80%	9.32%	11.25%
DRREDDY	71 Outperform	₹973.45B	17.04	―	0.63%	14.10%	9.72%
GLENMARK	53 Neutral	₹545.85B	54.31	―	0.24%	30.27%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
WOCKPHARMA	47 Neutral	₹223.81B	-996.96	―	―	1.19%	93.08%

Wockhardt Limited Corporate Events

Wockhardt Seeks Pan-European Approval for Novel Antibiotic WCK 5222

Wockhardt has filed a Marketing Authorisation Application with the European Medicines Agency for its novel antibiotic WCK 5222, branded as Zaynich, a fixed-dose combination of Zidebactam and Cefepime designed to treat resistant Gram-negative infections. The EMA has deemed the drug eligible for Accelerated Assessment, and Wockhardt expects approval across all EMA countries, complementing fast-track review already under way at the U.S. FDA and filings in India; as the first New Chemical Entity discovered and developed in India to seek pan-European authorisation, the move marks a significant milestone for both the company and the country’s innovation credentials in addressing life-threatening multi-drug resistant infections.